Zacks Investment Research upgraded shares of NOVO-NORDISK AS (NVO) from UNDERPERFORM to NEUTRAL on August 15, 2012, with a target price of $160.00.
Novo Nordisk is a world leader in insulin and diabetes care and also manufactures and markets a variety of other pharmaceutical products. Furthermore the company is the world's largest producer of industrial enzyme products. The company believes that everyone must care for the environment and our natural resources.
Get all Zacks Research Reports and be alerted to fast-breaking buy and sell opportunities every trading day.
To get a free copy of the research report on NOVO-NORDISK AS (NVO),
click here.
For more information about research offerings from Zacks Investment Research, visit
Zacks.com .
Be the first to comment